your partner in preclinical research

Latest Posts

> 2020 May

Urosphere acquires Urolead creating a center of excellence in preclinical urology.

Last December, the company has acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank reinforces Urosphere’s activities providing a full package of specifically relevant models in oncology, from cells to PDXs. "The acquisition of Urolead is an essential part of our development strategy aiming at offering a full package of drug discovery portfolio of services and capabilities in urology” said Dr. Philippe Lluel, CEO of Urosphere.  "This is an exciting development for Urosphere as we continue to grow and meet the needs of our clients." The company broadens its portofolio of preclinical models and expands its business offer from services, co-development of molecules to licensing of PDX models. For further information, please do not hesitate to contact us contact@urosphere.com

Read more

> 2019 Mar

Urosphere will be present at the European Association of Urology congress 2019.


    Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues.  It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.

Read more

> 2018 May

DMS : finalisation d’une étude préclinique sur le traitement des dysfonctions érectiles.

Voir le communiqué de presse

Read more

> 2017 Oct

AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st.

Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.

Read more

> 2017 Oct

Part of the Repositive PDX comsortium.

Urosphere / Urolead is proud to be part of the Repositive PDX comsortium.

Read more